可溶性糖蛋白VI是疑似肝素诱导性血小板减少症患者大出血的预测因子
在310例疑似肝素诱导性血小板减少症(HIT)住院成人患者中排除近期血小板输注者后分析256例,采用酶联免疫吸附试验检测血浆可溶性糖蛋白VI(sGPVI)水平。89例(34.8%)发生大出血事件,发生大出血者sGPVI中位数显著高于未发生者(49.09 vs 31.93 ng/mL;P < .001)。校正危重症、脓毒症、体外循环手术和血小板减少程度后,sGPVI >43 ng/mL与大出血独立相关(校正比值比2.81;95%置信区间1.51-5.23)。
要点
- 疑似HIT患者中89例(34.8%)发生大出血事件。
- 大出血患者sGPVI中位数49.09 ng/mL,显著高于无大出血者的31.93 ng/mL(P < .001)。
- sGPVI >43 ng/mL与大出血独立相关,校正比值比2.81(95%CI 1.51-5.23)。
核心结论
- 研究结果表明,sGPVI与疑似HIT住院患者的大出血相关,sGPVI可能成为预测疑似HIT患者出血风险的新型生物标志物。
研究设计与样本
- 研究纳入310例疑似HIT的住院成人患者,均在怀疑HIT时采集血样,采用酶联免疫吸附试验检测血浆sGPVI水平。
- 因血小板浓缩物中sGPVI水平高,排除采血前1天内接受血小板输注的患者54例,最终256例纳入分析。
- 采用多变量logistic回归评估sGPVI高 vs 低与国际血栓与止血学会大出血事件的关联,并校正其他已知出血危险因素。
主要发现
- 256例分析患者中89例(34.8%)发生大出血事件。
- 发生大出血事件患者sGPVI中位数显著高于未发生大出血事件患者(49.09 vs 31.93 ng/mL;P < .001)。
- 校正危重症、脓毒症、体外循环手术和血小板减少程度后,sGPVI >43 ng/mL与大出血独立相关(校正比值比2.81;95%置信区间1.51-5.23)。
关键数值与推荐
- sGPVI >43 ng/mL与大出血独立相关,校正比值比2.81(95%置信区间1.51-5.23)。
- 大出血事件按国际血栓与止血学会标准判定。
- sGPVI水平采用酶联免疫吸附试验检测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We have shown that patients with suspected heparin-induced thrombocytopenia (HIT) have a high incidence of major bleeding. Recent studies have implicated elevated soluble glycoprotein VI (sGPVI) levels as a potential risk factor for bleeding. We sought to determine if elevated sGPVI plasma levels are associated with major bleeding events in patients with suspected HIT. We used a cohort of 310 hospitalized adult patients with suspected HIT who had a blood sample collected at the time HIT was suspected. Plasma sGPVI levels were measured by using enzyme-linked immunosorbent assay. Patients were excluded who had received a platelet transfusion within 1 day of sample collection because of the high levels of sGPVI in platelet concentrates. We assessed the association of sGPVI (high vs low) with International Society on Thrombosis and Haemostasis major bleeding events by multivariable logistic regression, adjusting for other known risk factors for bleeding. Fifty-four patients were excluded due to recent platelet transfusion, leaving 256 patients for analysis. Eighty-nine (34.8%) patients had a major bleeding event. Median sGPVI levels were significantly elevated in patients with major bleeding events compared with those without major bleeding events (49.09 vs 31.93 ng/mL; P < .001). An sGPVI level >43 ng/mL was independently associated with major bleeding after adjustment for critical illness, sepsis, cardiopulmonary bypass surgery, and degree of thrombocytopenia (adjusted odds ratio, 2.81; 95% confidence interval, 1.51-5.23). Our findings suggest that sGPVI is associated with major bleeding in hospitalized patients with suspected HIT. sGPVI may be a novel biomarker to predict bleeding risk in patients with suspected HIT.
引用
- Pishko AM, Andrews RK, Gardiner EE, et al. Soluble glycoprotein VI is a predictor of major bleeding in patients with suspected heparin-induced thrombocytopenia. Blood Adv. 2020. PMID: 32915974. doi:10.1182/bloodadvances.2020002861
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。